1
|
Tadini MC, Fernandes FS, Ozelin SD, de Melo MRS, Mansur AL, de Toledo TB, de Albuquerque NCP, Tavares DC, Marquele-Oliveira F, de Oliveira ARM. Pharmacokinetic study of AmB-NP-GR: a new granule form with amphotericin B to treat leishmaniasis and fungal infections. Eur J Pharm Sci 2022; 173:106173. [PMID: 35331860 DOI: 10.1016/j.ejps.2022.106173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2021] [Revised: 03/18/2022] [Accepted: 03/20/2022] [Indexed: 11/03/2022]
Abstract
Amphotericin B (AmB) has been the gold standard to treat systemic fungal infections. The use of AmB is restricted to hospitals because it poses several risks, mainly risks related to its high nephrotoxicity. Given the importance of this drug in medicine, new therapeutics and AmB formulations with nanotechnological improvements are required and could bring many benefits to patients. A new drug formulation with gastro-resistant coated granules has been proposed. The lipid-based system containing AmB was produced and used as raw material in the granulation/coated process. The new developed formulation (AmB-NP-GR) was characterized by optical microscopy, granulometry, and atomic force microscopy (AFM) after disintegration test. AmB-NP-GR showed granular shape, with most granules measured between 250 and 500 µm (37 ± 7% w/w). The AFM images indicated that the granule formulation should disintegrate in the intestine, to release the lipid-based carriers, making them available for absorption and allowing them to reach the blood circulation. The developed formulation was administered to rats in a single dose of 4.0 or 8.0 mg kg-1 and the pharmacokinetics was studied. The samples were analyzed by liquid chromatography coupled to mass spectrometry. Before the pharmacokinetic studies were conducted, the bioanalytical method was validated according to the EMA guideline and all evaluated parameters agreed with this guideline. The pharmacokinetic results showed that Cmax was similar for both doses and that tmax was reached at 4-12 hours for dose of 4.0 mg kg-1 and 4 hours for dose of 8.0 mg kg-1. The half-life related to the dose of 8.0 mg kg-1 increased significantly compared to the dose of 4.0 mg kg-1 (an increase of more than 3 times). In addition, the mean residence time related to the dose of 8.0 mg kg-1 was 4 times higher than for the lower dose. The clearance value showed to be higher for the lower dose. Together, these results provide important conclusions for experimental design of other in vivo safety and efficacy studies of AmB-NP-GR.
Collapse
Affiliation(s)
- Maraine Catarina Tadini
- Departamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, 14040-901, Ribeirão Preto, SP, Brazil; Eleve Science Pesquisa e Desenvolvimento, Supera Parque Av. Dra. Nadir Aguiar, n. 1805, 14056-680, Ribeirão Preto, São Paulo, Brazil
| | | | - Saulo Duarte Ozelin
- University of Franca, Av. Dr. Armando Salles Oliveira, n. 201, 14404-600, Franca, SP, Brazil
| | | | - Ana Luiza Mansur
- Eleve Science Pesquisa e Desenvolvimento, Supera Parque Av. Dra. Nadir Aguiar, n. 1805, 14056-680, Ribeirão Preto, São Paulo, Brazil
| | - Thaís Bueno de Toledo
- Departamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, 14040-901, Ribeirão Preto, SP, Brazil; Eleve Science Pesquisa e Desenvolvimento, Supera Parque Av. Dra. Nadir Aguiar, n. 1805, 14056-680, Ribeirão Preto, São Paulo, Brazil
| | | | - Denise Crispim Tavares
- University of Franca, Av. Dr. Armando Salles Oliveira, n. 201, 14404-600, Franca, SP, Brazil
| | - Franciane Marquele-Oliveira
- Eleve Science Pesquisa e Desenvolvimento, Supera Parque Av. Dra. Nadir Aguiar, n. 1805, 14056-680, Ribeirão Preto, São Paulo, Brazil.
| | - Anderson Rodrigo Moraes de Oliveira
- Departamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, 14040-901, Ribeirão Preto, SP, Brazil.
| |
Collapse
|
2
|
Biliary amphotericin B pharmacokinetics and pharmacodynamics in critically ill liver transplant recipients receiving treatment with amphotericin B lipid formulations. Int J Antimicrob Agents 2015; 46:325-31. [PMID: 26119497 DOI: 10.1016/j.ijantimicag.2015.04.009] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2014] [Revised: 03/31/2015] [Accepted: 04/03/2015] [Indexed: 10/23/2022]
Abstract
Fungal cholangitis is a potentially life-threatening condition. As amphotericin B (AmB) has a broad antimycotic spectrum, in this study its biliary penetration and activity was determined in two patients treated with liposomal AmB (L-AmB) and in one patient receiving AmB colloidal dispersion (ABCD). Biliary and plasma AmB levels were quantified by high-performance liquid chromatography after purification by solid-phase extraction. For assessment of biliary AmB activity, isolates of Candida albicans, Candida tropicalis, Candida glabrata and Candida krusei were incubated in porcine bile at AmB concentrations of 0.025-5.00 mg/L. In addition, patient bile samples retrieved for AmB quantification were inoculated with the same Candida strains. Biliary AmB concentrations were lower and displayed a slower rise and decline than plasma levels. The highest penetration ratio, as expressed by the ratio between the area under the AmB concentration-time curve in bile and plasma (liberated AmB) over the sampling period (AUC0-n bile/AUC0-n LI plasma), was 0.28. Proliferation of C. albicans and C. tropicalis in bile was similar to that in culture medium, whereas growth of C. glabrata was diminished and proliferation of C. krusei was absent in bile. In comparison with culture medium, AmB activity decreased in spiked porcine bile. In all but one patient bile sample, fungal growth was delayed or lacking even when AmB was not detectable. However, no fungicidal effect was observed in patient bile at AmB concentrations up to 1.28 mg/L. Thus, a reliable response of fungal cholangitis to treatment with L-AmB or ABCD cannot be anticipated.
Collapse
|
5
|
Rowe A, Zhang L, Hussain A, Braet F, Ramzan I. Assessment and histological analysis of the IPRL technique for sequential in situ liver biopsy. COMPARATIVE HEPATOLOGY 2011; 10:7. [PMID: 21819626 PMCID: PMC3199742 DOI: 10.1186/1476-5926-10-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/10/2010] [Accepted: 08/08/2011] [Indexed: 11/10/2022]
Abstract
BACKGROUND The isolated perfused rat liver (IPRL) is a technique used in a wide range of liver studies. Typically livers are assessed at treatment end point. Techniques have been described to biopsy liver in the live rat and post-hepatectomy. RESULTS This paper describes a technique for obtaining two full and one partial lobe biopsies from the liver in situ during an IPRL experiment. Our approach of retaining the liver in situ assists in minimising liver capsule damage, and consequent leakage of perfusate, maintains the normal anatomical position of the liver during perfusion and helps to keep the liver warm and moist. Histological results from sequential lobe biopsies in control perfusions show that cytoplasmic vacuolation of hepatocytes is a sign of liver deterioration, and when it occurs it commences as a diffuse pattern which tends to develop a circumscribed, centrilobular pattern as perfusion progresses. CONCLUSIONS Liver lobe biopsies obtained using this method can be used to study temporal effects of drug treatments and are suitable for light and electron microscopy, and biochemical analyses.
Collapse
Affiliation(s)
- Anthony Rowe
- Faculty of Pharmacy, University of Sydney, NSW 2006, Australia.
| | | | | | | | | |
Collapse
|
6
|
Abstract
AIM: To investigate whether the major kavalactone kavain imposes adverse effects on the liver ultrastructure and function by affecting vascular and microvascular architecture and altering hepatocellular morphology.
METHODS: Kavain solution (10 &mgr;g/mL or 43.5 &mgr;mol/L) was perfused for 2 h in isolated rat livers. After standard fixation and tissue preparation, the samples were examined by scanning electron microscopy (SEM), transmission electron microscopy (TEM), and light microscopy (LM).
RESULTS: LM, SEM, and TEM examinations indicated kavain-treated rat livers (n = 4) displayed severe vascular and endothelial damage compared to control livers (n = 4).
CONCLUSION: The data so far support the hypothesis that kavain induces adverse effects on liver; additional investigations with other kavalactones and their effects on liver are urgently needed.
Collapse
|
7
|
Hong Y, Shaw PJ, Tattam BN, Nath CE, Earl JW, Stephen KR, McLachlan AJ. Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases. Eur J Clin Pharmacol 2006; 63:165-72. [PMID: 17180621 DOI: 10.1007/s00228-006-0240-x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2006] [Accepted: 11/17/2006] [Indexed: 10/23/2022]
Abstract
OBJECTIVE This study investigates the association of liposomal amphotericin B (L-AmB) with plasma proteins and its impact on the pharmacokinetics of L-AmB in paediatric patients with malignant diseases. METHODS Paediatric oncology patients (n = 39) who received multiple-doses of L-AmB were recruited into this study. The association of the drug with plasma lipoprotein was investigated using single vertical spin density gradient ultracentrifugation and quantitated with a validated HPLC assay. The unbound amphotericin B (AmB) in the plasma was separated by ultrafiltration and determined with a validated LC/MS/MS assay. RESULTS The ex vivo lipoprotein distribution of L-AmB found that 68.3 +/- 11.8% of the drug was associated with the high density lipoprotein (HDL) fraction, which demonstrated a significant inverse correlation with posterior Bayesian estimates of L-AmB clearance (r = -0.690, p < 0.01). The average of unbound fraction of AmB in plasma of patients administered with L-AmB was 0.005, but its relationship with L-AmB clearance did not reach a statistical significance. CONCLUSION L-AmB displays different lipoprotein distribution profile from that of the conventional AmB formulation, with L-AmB preferentially associated with HDL in plasma. The inverse correlation of L-AmB clearance to its HDL distribution contributes to the difference in the pharmacokinetic profile of L-AmB.
Collapse
Affiliation(s)
- Ying Hong
- Faculty of Pharmacy, University of Sydney, Pharmacy Building (A15), Sydney, NSW 2006, Australia
| | | | | | | | | | | | | |
Collapse
|
8
|
Hong Y, Ramzan I, McLachlan AJ. Hepatobiliary disposition of liposomal amphotericin B in the isolated perfused rat liver. J Pharm Sci 2005; 94:169-76. [PMID: 15761940 DOI: 10.1002/jps.20239] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
The hepatic distribution, biliary excretion, and mass balance of liposomal amphotericin B (L-AmB) were investigated in recirculated isolated perfused rat liver. The results were compared with those from the conventional AmB formulation, amphotericin B deoxycholate (D-AmB). L-AmB was introduced as a bolus into the perfusate reservoir, at doses of 1000, 4000, and 8000 mug, to achieve therapeutically relevant concentrations. AmB concentrations in perfusate, ultrafiltrate, bile, and liver homogenate over 120 min were measured using a validated high-performance liquid chromatography assay. AmB hepatic disposition in isolated perfused rat liver after L-AmB bolus was characterized by a higher recovery in perfusate (81.7 +/- 9.4%, n = 13) and a significant decrease in hepatic distribution (5.9 +/- 2.4% at low dose, 2.4 +/- 0.9% at medium dose, and 1.9 +/- 0.7% at high dose) compared with D-AmB (32.2 +/- 4.5% in perfusate, 52.1 +/- 8.2% in liver at the dose of 198 microg). Tissue-to-perfusate partition coefficient of L-AmB calculated at 120 min decreased dramatically with the dose and was approximately 100-fold less than that achieved with D-AmB at the high dose (0.17 +/- 0.11 in L-AmB versus 15.82 +/- 6.43 in D-AmB). AmB displayed negligible biliary excretion, representing <0.1% of the dose administered with L-AmB. Hepatic uptake clearance of L-AmB (CL(H,uptake)) decreased with the increase in perfusate area under the curve at each dose. The relationship between perfusate area under the curve and CL(H,uptake) was described by a parallel hepatic uptake clearance model. In conclusion, liposomal encapsulation significantly alters the hepatobiliary disposition of AmB; the ability of liposomes to sequester AmB and the dose-dependent hepatic uptake clearance may account for dose-form-dependent differences in AmB pharmacokinetics.
Collapse
Affiliation(s)
- Ying Hong
- Faculty of Pharmacy, University of Sydney, NSW 2006, Australia
| | | | | |
Collapse
|